The global pharmaceutical industry has been involved in a period of transformational change over approximately the last decade, moving from traditional product development methods and Pharmaceutical Quality Systems (PQS) towards holistic and patient-risk-based approaches to knowledge and lifecycle management as described by ICH Q8, Q9 and Q10. For the most part, this new focus on science, process control and patient risk has impacted the development and initial process validation expectations for new products, however there are also newly articulated regulatory expectations for “ongoing”, or “continued”, process verification during the entire commercial life of a pharmaceutical product. For many firms, especially small to mid size manufacturers, the most urgent issues in aligning with the new process validation lifecycle are not about new products at all, but rather center around the ongoing verification of existing, or “legacy”, products. Some of the common questions that arise include:
In an attempt to provide a multi-company view of these and other issues, the ISPE PV Team has drafted a paper addressing the concerns of firms attempting to implement the Process Validation Lifecycle generally and the Ongoing Process Verification phase specifically. Led by Senior Quality Managers from industry leading companies, the paper presents perspectives on both company-wide and individual-product strategies. It may be problematic for firms to simply increase all monitoring of all attributes to “statistical” levels, especially if there is not a well developed knowledge base and PQS to support the enhanced monitoring’s implementation. A “roadmap” to implementation may be needed. This paper is intended to help plan that journey for legacy product firms. Download the Process Validation Lifecycle Implementation for Existing (“Legacy”) Products discussion paper today!
The ISPE Advancing Pharmaceutical Quality (APQ) program team has been actively engaged with the US Food and Drug Administration’s (US FDA) Quality Management Maturity (QMM) program since its inception and along the...
The International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has recently announced the adoption of the revised guideline
The outlook for the biopharmaceutical market is promising, with expectations that the market will double in the next 10 years, resulting in new therapies and advances in biopharmaceutical manufacturing. This doesn't sound like much at first, but if you consider how the market has developed over the last 20 years, a doubling in the next 10 years is very significant.